Versant Venture Management, LLC

Investment Portfolio & 13F Holdings Analysis

About

Type: FundHoldings: 7Value: $60.2MLatest: 2025Q1

Versant Venture Management, LLC is an institutional investment manager that filed its latest Form 13F for 2025Q1, reporting 7 holdings worth $0.1 billion. Form 13F filings provide transparency into the equity holdings of institutional investment managers with over $100 million in assets under management. This page displays the most recent portfolio holdings, allowing investors to track position changes, new investments, and portfolio composition.

AI_NATIVE detailed information: This accession holds the following tickers:[
  "SKYE",
  "GLUE",
  "CTNM",
  "RPTX",
  null,
  null,
  "CRSP"
]

Filing Details

13F-HR • 2025-03-31

SEC FilingSEC DataHachi Filing

Report Date: 2025-03-31
Filing Date: 2025-05-07
Total Holdings: 7
Total Value: 60208868
Accession Number: 0000950123-25-004223
Form Type: 13F-HR
CIK: versant-venture-management
Manager Name: Versant-Venture-Management

Data Enrichment

71% identified

5 identified2 unidentified

Holdings

SEC FilingSEC DataHachi Filing

Manager:

7 positions • $60.2M total value

SEC FilingSEC DataHachi Filing

Manager:

Search and click to pin securities to the top

Sort by:

Monte Rosa Therapeutics, Inc.

GLUE|61225M102

Shares:5.7M

Value:$26.2M

% of Portfolio:43.6% ($26.2M/$60.2M)

CRISPR Therapeutics AG

CRSP|H17182108

Shares:498.6K

Value:$17.0M

% of Portfolio:28.2% ($17.0M/$60.2M)

Contineum Therapeutics, Inc.

CTNM|21217B100

Shares:918.2K

Value:$6.4M

% of Portfolio:10.6% ($6.4M/$60.2M)

Skye Bioscience, Inc.

SKYE|83086J200

Shares:2.0M

Value:$3.2M

% of Portfolio:5.3% ($3.2M/$60.2M)

Repare Therapeutics Inc.

RPTX|760273102

Shares:2.6M

Value:$2.6M

% of Portfolio:4.3% ($2.6M/$60.2M)

87978U207

Shares:3.5M

Value:$2.6M

% of Portfolio:4.3% ($2.6M/$60.2M)

00773U108

Shares:506.8K

Value:$2.2M

% of Portfolio:3.7% ($2.2M/$60.2M)

Instrument	Shares		Other Manager	Value	% of Portfolio
Monte Rosa Therapeutics, Inc.(GLUEcusip61225M102)	5.7M	QoQ 0.00% (-0) YoY NEW(+5.7M)	All Managers (Combined)	$26.2M	43.6% ($26.2M/$60.2M)	QoQ -33.14% (-$13.0M) YoY NEW(+$26.2M)
CRISPR Therapeutics AG(CRSPcusipH17182108)	498.6K	QoQ 0.00% (-0) YoY 0.00% (-0)	All Managers (Combined)	$17.0M	28.2% ($17.0M/$60.2M)	QoQ -13.54% (-$2.7M) YoY -50.07% (-$17.0M)
Contineum Therapeutics, Inc.(CTNMcusip21217B100)	918.2K	QoQ 0.00% (-0) YoY NEW(+918.2K)	All Managers (Combined)	$6.4M	10.6% ($6.4M/$60.2M)	QoQ -52.35% (-$7.0M) YoY NEW(+$6.4M)
Skye Bioscience, Inc.(SKYEcusip83086J200)	2.0M	QoQ 0.00% (-0) YoY 0.00% (-2)	All Managers (Combined)	$3.2M	5.3% ($3.2M/$60.2M)	QoQ -43.81% (-$2.5M) YoY -89.83% (-$28.2M)
Repare Therapeutics Inc.(RPTXcusip760273102)	2.6M	QoQ 0.00% (-0) YoY 0.00% (-0)	All Managers (Combined)	$2.6M	4.3% ($2.6M/$60.2M)	QoQ -24.74% (-$857.8K) YoY -79.06% (-$9.9M)
(cusip87978U207)✕	3.5M	QoQ NEW(+3.5M) YoY NEW(+3.5M)	All Managers (Combined)	$2.6M	4.3% ($2.6M/$60.2M)	QoQ NEW(+$2.6M) YoY NEW(+$2.6M)
(cusip00773U108)✕	506.8K	QoQ 0.00% (-0) YoY 0.00% (-1)	All Managers (Combined)	$2.2M	3.7% ($2.2M/$60.2M)	QoQ -6.42% (-$152.0K) YoY -69.09% (-$5.0M)